Genetically informed drug target prioritisation and repurposing for major depressive disorder

Abigail R. ter Kuile[1], Chris Finan[2,3,4], Sandesh Chopade[2], Marion Van Vugt[2,4,5], Nikita Hukerikar[6], Serena Barral[7], Argyris Stringaris[1,8], Amand F. Schmidt[2,3,5], Karoline Kuchenbaecker[8], Jean-Baptiste Pingault[1,9]

Affiliations

1. Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom
2. Institute of Cardiovascular Science, University College London, London, United Kingdom
3. The National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK
4. Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
5. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
6. Institute of Health Informatics, University College London, London, United Kingdom
7. Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL GOS Institute of Child Health, University College London, London, United Kingdom
8. Division of Psychiatry, University College London, London, United Kingdom
9. Social Genetic and Developmental Psychiatry, King's College London, London, United Kingdom

Abstract

Major depressive disorder (MDD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MDD drug targets, leveraging genome-wide association study (GWAS) summary statistics from >525,000 MDD cases. We derived exposure data from 10 GWAS measuring protein quantitative trait loci (pQTLs) and gene expression levels (eQTLs) in blood, cerebrospinal fluid, and brain tissues. We performed *cis*-Mendelian randomisation (MR) on 3,469 druggable targets (genes encoding proteins targeted by existing compounds or experimentally predicted to be druggable). To strengthen causal inference, we implemented robust MR estimators, colocalisation, external replication, and assessed directional consistency across tissues. We integrated MR effect directions with drug mechanisms and clinical annotations to infer potential therapeutic effects. Validation analyses showed that 82% of drugs approved for depression/anxiety had ≥1 significant MR target, compared to 51% for compounds in clinical trials. For repurposing, we prioritised 54 targets of compounds developed for other conditions with estimated beneficial effects on MDD (compound mechanisms that counteract target risk-increasing effects). Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MDD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.

Introduction

Major depressive disorder (MDD) is common and a leading cause of years lived with disability globally [1]. Current pharmacological treatments are ineffective for many with MDD, with only one-third of patients reaching remission after first-line antidepressant treatment [2]. Furthermore, 28-40% of patients are classified as having treatment-resistant depression, defined as not remitting after the prescription of two or more antidepressants [2,3]. Currently approved drugs target a narrow range of therapeutic mechanisms, with most antidepressants acting on monoaminergic neurotransmitter systems [4]. The lack of novel pharmacological treatments for MDD highlights the pressing need for innovative strategies to facilitate efficient drug discovery.

Human genetics offers a promising avenue to guide the development of pharmacological treatments. Drugs acting on targets with supporting human genetic evidence are 2.6 times more likely to succeed in drug discovery pipelines and progress into clinical practice than those without [5–7]. This is reflected in recent FDA approvals: 63% of drugs approved in the past decade had genetic support [8]. Given that genes encode proteins, which constitute over 90% of drug targets, genetic methods can identify disease-associated protein targets suitable for repurposing existing drugs or for novel development opportunities [9,10]. To accelerate discovery and repurposing, an efficient strategy involves focusing on the 'druggable genome' rather than all protein-coding genes, reducing the multiple testing burden [9–11]. The druggable genome comprises genes encoding proteins targeted by drugs that are already approved, those at the clinical stage of drug development, or those potentially druggable based on experimental evidence [9].

Mendelian randomisation (MR) enables scanning of the druggable genome by using genetic variants as instruments to estimate the effect of altering each drug target's activity on disease risk [12]. For each target protein, genetic variants selected as instruments lie within and around the gene encoding that protein (*cis*-region) [11]. These instruments are associated with individual variation in a molecular trait in a given tissue, including changes in protein values or mRNA expression [10]. *Cis*-MR leverages data from genome-wide association studies (GWAS) to obtain the effects of each selected variant on both the exposure (target protein activity) and the outcome (MDD). To infer exposure-outcome causal effects, MR assumes that variant effects on the outcome operate through the exposure and are independent of confounders [12]. Under these assumptions, a significant MR estimate provides genetic evidence suggesting that modulating the protein corresponding to the instrumented *cis*-region may influence the disease process, making it a candidate drug

target for that outcome [10,12]. MR has key advantages for identifying drug targets. First, the random assortment of genetic variants at conception mimics treatment allocation in randomised controlled trials, strengthening causal inference regarding target effects on disease outcomes [13]. Second, MR provides the direction of effect to infer whether activating or inhibiting a target would mitigate disease risk [14]. The effect direction can then be combined with pharmacological data on existing drugs to identify target-compound pairs with aligned mechanisms, thus directly aiding repurposing [14,15].

To conduct drug target MR, a large-scale GWAS of the disease outcome of interest is fundamental. The latest Psychiatric Genomics Consortium (PGC) Phase 3 MDD GWAS offers unprecedented opportunities in this regard. The meta-analysis found 635 genomic loci associated with MDD, of which 293 are novel [16]. Alongside identifying over 300 high-confidence genes and associated pathways, the study performed drug target enrichment analyses [16]. Using sets of genes encoding protein targets of drugs and grouping them by drug classes showed that antidepressant and antipsychotic drug classes were enriched for MDD-associated variants [16]. Additionally, 18 individual compounds approved mainly for indications other than depression were enriched, including anti-cancer drugs, antipsychotics, and medications for anxiety (pregabalin) and narcolepsy (modafinil) [16]. However, as noted by the authors, enrichment analysis is not directional and cannot distinguish whether implicated compounds might increase or decrease MDD symptoms [16]. Enrichment of established antidepressant drug class alongside potential repurposing opportunities underscores the value of this large-scale GWAS dataset for a detailed and directional drug target MR interrogation.

While initial applications of *cis*-MR to MDD exploring the druggable genome have provided a foundation by inferring directional effects [17,18], key opportunities remain to advance and strengthen this approach. The current study addresses this by introducing an integrated approach that leverages several methodological advances to robustly identify and prioritise targets. First, we enhance statistical power by using the latest large-scale PGC Phase 3 MDD GWAS [16]. Second, we expand the scope of the druggable genome beyond established actionable targets to include novel candidates supported by experimental evidence of druggability. Third, we evaluate target effects across blood, cerebrospinal fluid (CSF), and multiple brain regions, extending beyond previous brain-restricted analyses [17,18]. Finally, our framework strengthens the validation of genetic evidence by employing multiple robust MR estimators, colocalisation, external replication, and tissue-specific directional consistency.

To identify a tractable set of high-priority drug targets from our MR findings for experimental and clinical validation, we systematically integrated genetic evidence with biological, clinical and pharmacological data. Such a framework has been applied to *cis*-MR targets in other non-psychiatric complex diseases, evaluating the genetic robustness, biological plausibility, clinical relevance, and pharmacological annotations of target-compound pairs [14,15,19]. These studies integrated target effect directions with pharmacological mechanisms and clinical profiles of existing drugs [14,15,19]. Aligning the genetically estimated benefit of modulating a target with the mechanisms of drugs approved for other indications can identify high-confidence repurposing candidates [14,15]. The approach was validated by genetically recapitulating established pharmacological treatments for diseases, known as 'positive controls' [14,15]. Applying this framework to MDD is particularly pertinent, where therapeutic mechanisms are thought to be complex [4]. Addressing a gap in prior MDD drug target MR investigations [17,18], we also evaluate established antidepressant targets as positive controls to benchmark analyses and strengthen prioritisation of novel candidates.

In this study, we applied an integrated genetic and pharmacological framework to systematically identify and prioritise drug targets for MDD within the druggable genome. First, we aimed to identify targets using *cis*-MR and assess the genetic robustness of findings through multiple sensitivity analyses. Second, we sought to validate our approach using established MDD target-compound pairs as positive controls. Third, we aimed to characterise drug repurposing opportunities by integrating genetic effects with drug mechanisms of action and clinical annotations (e.g., primary indications and side effects).

Methods

<u>Outcome and exposure data</u>

GWAS summary statistics

For our outcome phenotype, we used summary statistics from the PGC MDD phase 3 GWAS meta-analysis of 525,197 MDD cases and 3,362,335 controls of European genetic ancestry (PGC MDD-3) [16]. For our primary analysis, we used 10 GWAS of protein or transcript values measured in blood [20–22], cerebrospinal fluid (CSF) [23], or multiple brain regions [24,25] to derive genetic instruments for exposure variables (Supplementary Table 1). These genetic variants are quantitative trait loci (QTLs) strongly associated with changes in protein levels (pQTLs) or mRNA expression (eQTLs) in each tissue [10]. We analysed each protein/transcript GWAS separately (hereafter referred to as a 'panel'). Among these, the blood plasma proteomic data included two pQTL panels measured using different protein assay platforms (deCODE using SomaScan and UK Biobank Pharma Proteomics Project [UKB-PPP] using Olink) [20,21], which maximised protein coverage and enabled cross-platform validation (Supplementary Methods) [26].

Drug target data

To select targets for *cis*-MR analysis, we used the hierarchical druggability assessment framework from Open Targets [27]. We included all targets with clinical trial evidence from ChEMBL [28], with the following hierarchy: approved drugs (phase IV, established druggability, i.e. already 'drugged'), advanced clinical development (phases II-III), and early clinical development (phase I). For targets with only experimental evidence (i.e. potentially druggable), we retained those within the top tier of experimental quality assessments from Open Targets hierarchical scoring (Supplementary Methods). This experimental data was used to incorporate promising targets for future drug discovery exploration. Our approach resulted in 3,652 genes encoding drug target proteins, comprising 1,452 targets with clinical trial evidence (935 phase IV, 489 phase II-III, 28 phase I) and 2,200 with high-quality experimental evidence.

<u>Primary Mendelian Randomisation (MR) analysis</u>

We used purpose-built Python packages for *cis*-MR analyses [19]. We selected genetic variants as instruments among exposure QTLs with minor allele frequencies (MAF) > 0.01, within 200kb of the *cis*-gene encoding one of 3,652 drug target proteins [29], and with exposure GWAS p-value < 1×10^{-6}. We applied MR Steiger filtering to minimise reverse

causation by removing variants with a greater effect on the outcome than on the exposure. Variants were clumped to a linkage disequilibrium (LD) R-squared threshold of 0.4, with remaining correlations between instruments accounted for by generalised least squares modelling. LD reference matrices were derived from a random subset of 5,000 UK Biobank participants of European genetic ancestry [30]. For single-variant targets we employed the Wald ratio estimator (MR-Wald), and for multiple-variant targets, the generalised least squares implementation of the inverse-variance weighted estimator (MR-IVW), allowing for correlated instruments [31]. To mitigate potential horizontal pleiotropy in our IVW analysis, we applied heterogeneity-based pruning of variants with large leverage (>3 times the mean) or outlier statistics (chi-square >11) [19,32]. For targets with <4 IVs, we selected fixed-effects IVW model estimates and random-effects for those with ≥4 IVs [33,34].

A total of 3,469 targets of the 3,652 in the druggable genome had instrument(s) that passed our filtering criteria and were tested in MR. We corrected for multiple testing by applying a Bonferroni correction p-value threshold of $3.9×10^{-6}$ (0.05/12,794 total MR-IVW/-Wald tests across 10 panels spanning blood, brain and CSF). We used the total number of tests rather than unique targets tested, as most targets (94.2%) were tested more than once across exposure panels (Supplementary Table 2).

Sensitivity analyses and target annotation

MR-IVW robustness

We conducted sensitivity analyses using robust MR methods for each target with significant MR-IVW effects in our primary MR analyses. We employed three robust methods with different assumptions about instrument validity [35] across four models: generalised least squares implementation of MR-Egger with and without heterogeneity-based pruning (i.e. two models) [36], contamination mixture [37], and weighted median methods [38] (Supplementary Methods). We applied a Bonferroni-corrected p-value threshold of $7.2×10^{-5}$, accounting for 693 significant IVW estimates that we sought to test with robust MR. Robust MR estimates that were significant and directionally consistent with IVW estimates for that target provided stronger evidence for the validity of our causal estimates [35]. Targets with significant but inconsistent directional effects across IVW and robust methods were deprioritised.

External pQTL replication

We performed external replication of targets significant in our primary *cis*-MR analyses in independent QTL datasets, focusing on panels with a matching molecular phenotype modality (i.e. pQTL) and tissue type (i.e., blood or brain) to our discovery panels (Supplementary Methods). We used the same parameters for replication analyses as those applied in our primary MR analysis. We applied tissue-specific Bonferroni corrections, with separate thresholds for blood and brain based on the number of significant targets carried forward from their respective discovery panels to replication panels (Supplementary Table 3). We defined successful replication as a significant MR-IVW/-Wald effect in the replication panel that was directionally consistent with the discovery panel effect estimate. The eQTL targets were not tested for external replication as they were derived from large-scale meta-analyses for which comparably well-powered independent datasets were unavailable.

Colocalisation

We performed colocalisation analyses for each significant MR-IVW/-Wald target in a given QTL panel to evaluate whether molecular traits (pQTL/eQTL) and MDD share causal variants. We used the *coloc* R package and the *'coloc.abf'* function (Supplementary Methods) [39] with a posterior probability threshold of ≥ 0.8 to indicate strong evidence. Strong evidence for PPH4 indicates a shared causal variant between the molecular trait and MDD offering triangulation of evidence alongside *cis*-MR [29,40]. Conversely, strong PPH3 evidence indicates distinct causal variants for each trait, suggesting potential violations of MR assumptions due to, for example, linkage disequilibrium, or pleiotropic pathways through neighbouring genes [29,40].

Estimated therapeutic relevance

To evaluate the therapeutic relevance of drug targets with significant *cis*-MR effects, we integrated our genetic findings with drug mechanisms of action data from ChEMBL [28]. We determined whether existing compounds targeting that protein would act in a potentially beneficial direction based on the MR-IVW/-Wald effect direction (Supplementary Methods). We classified therapeutic directional effects as 1) 'beneficial', where the drug's mechanism mitigates the risk-increasing effect of the target on MDD (e.g., an inhibitor for a target whose increased expression increases MDD risk); 2) 'adverse', the drug's mechanism is in the same direction as the target's risk-increasing effect; or 3) 'unknown', the relationship could not be classified (e.g., for mechanisms that do not specify inhibition or activation).

Known depression-related drug effects

We extracted known depression-related therapeutic applications or side effects for each compound in the target-compound pair list used in our estimated therapeutic directional analysis. We classified drug effects using core depression terms (MDD, depression, apathy, mood, anxiety, suicidality) and broader depression-relevant terms encompassing related psychiatric and somatic symptoms (Supplementary Methods). Drug effects data were extracted from databases of drugs licensed in the UK (primary therapeutic indications, side effects, cautions, and contraindications) and ChEMBL (primary compound indications in clinical trial phases I-IV) [28]. Depression-related clinical effects for compounds targeting genetically supported MDD proteins suggest biological relevance, including adverse effects. Targets can be modulated by multiple drugs with different mechanisms (activators or inhibitors), allowing for the development of novel drugs to counteract adverse effects. Furthermore, as documented in databases of medications licensed in the UK, approved antidepressants have reported psychiatric side effects, including mood changes and anxiety. Thus, depression-related symptoms as side effects do not necessarily preclude therapeutic potential.

Target prioritisation

We evaluated significant MR-IVW/-Wald drug targets from our primary analysis by considering evidence for each target across assessments of genetic robustness and therapeutic potential.

Genetic robustness assessment

To evaluate genetic evidence, we incorporated four assessments. First, we favoured targets with predominantly consistent directional *cis*-MR effects across multiple discovery panels within the same tissue type (brain or blood). We excluded blood pQTL targets with directionally opposite *cis*-MR effects between panels using different protein assay platforms, indicating technical artefacts in protein measurement (Supplementary Methods). Second, we favoured targets with robust MR estimates that aligned with the primary MR-IVW effect direction and excluded those with directional disagreement. Third, we prioritised targets with PPH4 colocalisation evidence, excluding those with PPH3 evidence. Fourth, we prioritised pQTL targets with external replication. Not all targets had sufficient data or statistical power to be evaluated by each of these criteria. We therefore prioritised targets that met at least one of these genetic robustness assessments, alongside supporting therapeutic potential.

Therapeutic potential assessment

To assess the therapeutic potential of novel MDD targets, we focused on identifying repurposing candidates, defined as targets of drugs approved for the treatment of non-psychiatric conditions. We also considered targets of compounds tested in clinical trials for indications other than depression or anxiety. We evaluated clinical relevance by identifying targets with compounds developed for other conditions that showed depression-related drug effects. We integrated our therapeutic beneficial compound analysis by prioritising targets with at least one compound that has mechanisms acting in a direction that would oppose the target risk-increasing effect indicated by our MR results.

Final prioritisation criteria

We defined prioritised targets as those meeting two criteria: 1) either ≥1 genetic robustness evidence or targeted by compounds showing depression-related drug effects, and 2) targeted by ≥1 compound(s) with estimated beneficial therapeutic directions. We categorised prioritised targets by tissue expression (brain-only, blood-only or brain and blood). We investigated brain-only targets as high-priority candidates given the neurobiological basis of MDD and that tissue-specific targets may produce fewer off-target effects than those ubiquitously expressed [41]. We defined high-priority brain targets as those meeting both of the following criteria through literature searches: 1) blood-brain barrier permeability of estimated beneficial compounds, and 2) the target's role in depression-relevant pathophysiological mechanisms. This included literature on the target function in relevant biological processes, animal model studies demonstrating antidepressant-like or anxiolytic-like effects of beneficial target modulation, and observational studies showing associations between the use of beneficial compounds and reduced symptoms of depression or anxiety.

Positive control analysis

We identified positive controls (PCs), also known as genetic rediscoveries of known drug-target mechanisms, using drug effects data from ChEMBL and databases of drugs licensed in the UK. We selected targets of drugs with primary indications for depression and/or anxiety and classified them as approved PC targets (our primary positive controls, targeted by drugs in phase IV) and clinical trial PC targets (our secondary positive controls, targeted by compounds in clinical trial phases I-III). We included anxiety due to the high comorbidity, treatment overlap and genetic overlap between anxiety disorders and MDD, with genetic correlations approaching unity (~0.9) [42–44]. As a single compound can act on multiple targets, we also analysed our results at the compound level. We were able to test in *cis*-MR

targets for 61 approved compounds and 169 clinical trial compounds. Compounds approved for one indication (e.g. MDD) but in clinical trials for another (e.g. anxiety) were classified only in the approved category. At the target level, we tested 80 approved PC targets and 205 clinical PC targets. We note that 76 approved PC targets overlapped with clinical trial PC targets, reflecting that targets of approved drugs are also targets of other compounds tested in clinical trial phases I-III.

We conducted enrichment analyses to assess whether our *cis*-MR approach identified known drug targets for depression. We categorised tested targets for comparison into: 1) approved PC targets versus all other targets, and 2) clinical trial PC targets versus all other non-PC targets. We constructed contingency tables for brain and blood tissues separately, counting targets with significant and non-significant *cis*-MR estimates in each category. Comparisons were restricted to brain and blood due to the limited number of targets found in CSF. Odds ratios (OR) quantified enrichment, with OR > 1 indicating higher odds of PC targets among significant results. Statistical significance was tested using chi-square tests (Supplementary Methods).

Results

Overview

Our primary *cis*-MR analysis identified 564 unique drug targets (of 3,469 tested) significantly associated with MDD across at least one of ten panels of protein or transcript values measured in blood, brain, and CSF. We evaluated significant targets by integrating evidence for genetic robustness and therapeutic potential (**Figure 1**). Results for all significant *cis*-MR targets are presented in Supplementary Tables 4 and 5, with a summary provided in Supplementary Table 6.

Figure 1: Novel target identification and prioritisation workflow. *Flow diagram showing systematic identification of 10 high-priority novel drug targets for major depressive disorder from 3,469 druggable genome targets tested in cis-Mendelian randomisation.*

<u>Positive control (PC) analysis</u>

Our *cis*-MR analysis demonstrated stronger genetic support for compounds in clinical trial phase IV for depression and anxiety (approved positive controls (PC)) than those in clinical trial I-III (clinical trial PCs). At the drug level, 50/61 (82%) approved PCs showed at least one significant MR target effect on MDD, compared to 86/169 (50.9%) for clinical trial PC compounds (Supplementary Table 7). Of the significant approved PC compounds, 46% had indications for depression only, 18% for both depression and anxiety, and 36% for anxiety only. For clinical trial PC compounds, 46.5% were tested in clinical trials for depression only, 41.9% for depression and anxiety, and 11.6% for anxiety only.

Of the approved PC drugs with significant targets, most showed estimated beneficial mechanisms of action. Specifically, 27 drugs (54%) had targets with exclusively beneficial effects (where drug mechanisms oppose target MDD risk directions indicated by MR), while 13 drugs (26%) with multiple targets showed mixed effects (i.e. beneficial on some targets, adverse on others). Only 4 (8%) exhibited exclusively adverse effects, and 6 (12%) had unknown directionality. For compounds undergoing clinical trials, 29 (33.7%) showed beneficial mechanisms, 24 (27.9%) had mixed effects, 15 (17.4%) demonstrated adverse effects, and 18 (20.9%) had unknown directionality. **Table 1** presents results for targets of key positive controls with significant MR effects and estimated therapeutic directions that align with their known clinical efficacy for MDD and/or anxiety.

When examining individual drug targets of positive controls rather than compounds, we found significant enrichment of targets of approved PC compounds in brain tissues (OR=1.97, 95% CI=1.11-3.49, p=0.018). Approved PC targets had a 1.7-fold higher rate of significant MR estimates (18.8%) in the brain compared to other targets (10.5%). Notably, the target-level significance rate differs from the higher compound-level rate (82%) because most drugs act on multiple targets, with compounds requiring only one significant target to be counted at the compound level. Analyses at the target level allowed us to identify which specific proteins within multi-target compounds showed genetic evidence of relevance to MDD.

Targets of clinical trial PCs showed similar brain-specific enrichment (OR=1.54, 95% CI=1.02-2.30, p=0.036), with a 14.9% significance rate compared to 9.1% for non-PC targets. Enrichment was not significant in blood tissues for either approved PC targets (OR=1.81, 95% CI=0.75-4.35, p=0.289) or clinical trial PC targets (OR=1.10, 95% CI=0.60-

2.03, p=0.756; Supplementary Table 8). Stronger *cis*-MR evidence for positive controls in brain tissues supports the biological validity of our approach, aligning with the neurobiological aetiology of MDD and with established pharmacological interventions targeting neurotransmitter systems and neural circuitry [45].

Table 1: Drug targets of positive control compounds for depression and anxiety with significant MR effects and estimated beneficial therapeutic directions on MDD.

Target	Tissue (MR effect direction)	Supporting genetic evidence	Estimated therapeutic MOA & drug MOA	Compounds with aligned MOA	Primary indications
Monoamine signalling					
Sodium-dependent serotonin transporter: *SLC6A4*	eQTL blood (+)	Effect direction aligned with beneficial MOA therapeutic effects	Inhibition (-), 28 inhibitors/ antagonists (-)	21 SSRIs/SNRIs, TCAs, atypical antidepressants	Depression & anxiety
Sodium-dependent dopamine transporter: *SLC6A3*	eQTL cortex (+)	Effect direction aligned with beneficial MOA therapeutic effects	Inhibition (-), 10 inhibitors (-)	bupropion	Depression, ADHD (e.g. methylphenidate)
Dopamine receptor D2: *DRD2*	eQTLs (+): basal ganglia, hippocampus, spinal cord	Directional consistency, aligned with beneficial MOA therapeutic effects	Inhibition (-), 46 antagonists/ inhibitors (-)	amoxapine, quetiapine prochlorperazine	Depression, anxiety, bipolar disorder, schizophrenia
Histamine H1 receptor: *HRH1*	eQTL cortex (+), eQTL blood (+)	Directional consistency, aligned with beneficial MOA therapeutic effects	Inhibition (-), 62 antagonists/ inverse agonists (-)	hydroxyzine, dibenzepin	Depression & anxiety
Glutamatergic signalling					
NMDA receptor subunits: GRIN1 (+) GRIN2D (+) GRIN2A (-)	pQTL DLPFC (+), eQTL cerebellum (-), pQTL blood (+)	Largely consistent effect across subunits (+) aligned with beneficial MOA therapeutic effects	Inhibition/ activation (-/+), 21 negative allosteric modulator/ antagonists/ blocker (-)	esketamine	Treatment-resistant depression

Table 1: Drug targets of positive control compounds for depression and anxiety with significant MR effects and estimated beneficial therapeutic directions on MDD.

Target	Tissue (MR effect direction)	Supporting genetic evidence	Estimated therapeutic MOA & drug MOA	Compounds with aligned MOA	Primary indications
GABA Signalling					
GABA(A) receptor subunits: *GABRA6* (-) *GABRB2* (-) *GABRG2* (-), *GABRP* (+)	eQTL cerebellum (-/+)	Largely Consistent effect across subunits (-) aligned with beneficial MOA therapeutic effects of anxiolytics	Inhibition/ activation (-/+), 59 positive allosteric modulators/ agonist (+)	benzodiazepines, brexanolone, meprobamate	Anxiety, insomnia, anxiety with depressive symptoms, postpartum depression
Calcium Ion Channel Modulators					
Calcium channel subunits: *CACNG2* (+) *CACNA2D2* (+) *CACNA2D4* (-)	eQTL cortex (+/-)	Largely consistent effect across subunits (+)	Inhibition/ activation (-/+), modulators, blockers (-)	pregabalin	Generalised anxiety disorder, epilepsy, nerve pain
Targets of compounds in clinical trials for depression/anxiety					
Phosphodiesterases: *PDE6B* (+), *PDE6G* (+), *PDE6H* (+) *PDE3B* (+) *PDE6C* (-)	eQTL blood (+/-)	Largely consistent effect across subtypes (+) aligned with beneficial MOA	Inhibition/ activation (-/+), inhibitors (-)	9 inhibitors, e.g, pentoxifylline dipyridamole	Cardiovascular (IV), depression (I-II)
Corticotropin -releasing factor receptor 1: *CRHR1*	eQTLs: cerebellum (-), cortex (+)	Cortex effect (+) aligned with beneficial MOA	Inhibition/ activation (-/+), 5 antagonists (-)	5 in clinical trial: e.g. verucerfont, emicerfont, pexacerfont	Depression & anxiety (I-II)

Note: A positive (+) MR effect indicates higher expression increases MDD risk, suggesting beneficial compounds would have inhibitory (-) mechanisms of action (MOA) on the target; a negative (-) MR effect indicates lower expression increases risk, suggesting beneficial compounds would have activating (+) mechanisms of action. Consistent MR effect directions across related subunits/subtypes, concordance between tissues, and agreement between genetically estimated therapeutic direction and known clinical efficacy of established drug mechanisms strengthen the validity of our findings. ADHD, attention-deficit/hyperactivity disorder; DLPFC, dorsolateral prefrontal cortex; eQTL, expression quantitative trait loci; MDD, major depressive disorder; MOA, mechanism of action; MR, Mendelian randomisation; pQTL, protein quantitative trait loci.

Prioritisation of novel targets for repurposing

We identified 523 drug targets beyond those currently used or explored in depression treatment. Following our systematic prioritisation framework (**Figure 1**), 216 targets met criteria for genetic robustness evidence or clinical relevance, of which 54 were prioritised due to being targeted by compounds with estimated beneficial therapeutic directions for MDD. Tissue expression patterns of prioritised targets included four found in both brain and blood panels, 31 brain-only targets, and 19 blood-only targets. Of the 31 targets exhibiting brain-specific effects, 10 met our high-priority criteria with blood-brain barrier-penetrant compounds and supporting literature for depression-relevant mechanisms (**Table 2** and Supplementary Table 9).

Table 2: High-priority brain targets of novel compounds with estimated beneficial therapeutic directions on MDD.						
Target	Tissue (MR effect)	Supporting genetic evidence	Estimated therapeutic MOA & drug MOA	Beneficial compounds	Primary indications (depression-related side effects/ clinical trial phase)	Depression relevant mechanisms
Cyclin-dependent kinase 4: *CDK4*	eQTLs: basal ganglia (-), cerebellum (-), hippocampus (-), spinal cord (-), pQTL DLPFC (+)	Directional consistency eQTL brain, external replication pQTL	Mixed: inhibition/ activation (-/+), inhibitor (-)	Crosses BBB: abemaciclib, palbociclib	Breast cancer (fatigue, appetite, psychiatric)	Neuroplasticity, neural activity, neurogenesis
Nischarin Imidazoline receptor 1: *NISCH*	eQTLs: cerebellum (+), hippocampus (+), spinal cord (-)	Directional consistency cerebellum & hippocampus	Mixed: inhibition/ activation (-/+), agonist (+)	Crosses BBB: moxonidine, rilmenidine	Hypertension (insomnia, anxiety, depression, psychiatric)	Sympathetic regulation, stress response, target activation has animal model antidepressant-like effects
Nitric oxide synthase, inducible: *NOS2*	eQTLs: cortex (+), basal ganglia (+), cerebellum (+)	Directional consistency	Inhibition (-), inhibitor (-)	Clinical trial: tilarginine, KD7040, GW-274150; crosses BBB: BN-4	Clinical trial: cardiogenic shock (III), migraine (II)	Neuroinflammation, oxidative stress, target inhibition has animal model antidepressant-like effects
Glutaminase kidney isoform, mitochondrial: *GLS*	eQTLs: cortex (+), cerebellum (+)	Directional consistency	Inhibition (-), inhibitor (-)	Clinical trial: telaglenastat; crosses BBB: JHU-083	Clinical trial: cancer (II)	Neuroinflammation, glutamate signalling, target inhibition has animal model antidepressant-like effects
Neurotrophic receptor tyrosine kinase 3: *NTRK3*	eQTL cortex (+)	Colocalisation	Inhibition (-), inhibitor (-)	Crosses BBB: entrectinib, larotrectinib	Cancer (anxiety, depression, psychiatric, mood, appetite/weight, fatigue/sleep)	Neuroplasticity, monoamine signalling, HPA axis regulation

Table 2: High-priority brain targets of novel compounds with estimated beneficial therapeutic directions on MDD.

Target	Tissue (MR effect)	Supporting genetic evidence	Estimated therapeutic MOA & drug MOA	Beneficial compounds	Primary indications (depression-related side effects/ clinical trial phase)	Depression relevant mechanisms
Angiotensin-converting enzyme: *ACE*	eQTL cortex (+)	MR effect direction aligns with drug MOA & reported mental health benefits	Inhibition (-), inhibitor (-)	Crosses BBB: e.g. captopril, fosinopril, lisinopril	Hypertension (anxiety, depression, mood, appetite/weight, insomnia/sleep)	Neuroinflammation, synaptic plasticity, serotonergic signalling, stress response, target inhibition associated with mood improvements in observational studies
Complex I NADH dehydrogenase subunits: *NDUFA2* (+) *NDUFB6* (+) *NDUFS1* (+)	eQTL cortex (+)	Consistent effect across subunits, robust MR support, reported mental health benefits	Inhibition (-), inhibitor (-)	Crosses BBB: metformin	Type 2 diabetes (appetite)	Mitochondrial function, neuroinflammation, metformin has animal model antidepressant-like effects and associated with mood improvements in observational studies
Hepatocyte growth factor receptor: *MET*	eQTLs: basal ganglia (+), spinal cord (+)	Directional consistency	Inhibition (-), inhibitor (-)	Crosses BBB: crizotinib, capmatinib	Cancer (appetite, fatigue, psychiatric)	Neuroplasticity, neurotrophic signalling, neuroinflammation

Prioritised targets with novel repurposing opportunities for MDD, i.e. drugs already approved or > Phase I for other indications but not in clinical trial for depression/anxiety as a primary indication. A positive (+) MR effect indicates higher expression increases MDD risk, suggesting beneficial compounds would have inhibitory (-) mechanisms of action (MOA) on the target; a negative (-) MR effect indicates lower expression increases risk, suggesting beneficial compounds would have activating (+) mechanisms of action. Brain targets were prioritised based on: availability of compounds acting in the beneficial direction for at least one tissue, plus clinical relevance (depression-related side effects) or ≥ 1 robust genetic evidence (significant MR effects with directional consistency in multiple brain/nervous system tissues, robust MR support, colocalisation support or pQTL external replication), plus compounds with blood-brain-barrier permeability and plausible depression-relevant biological mechanisms including pre-clinical evidence. BBB, blood-brain barrier; DLPFC, dorsolateral prefrontal cortex; eQTL, expression quantitative trait loci; MDD, major depressive disorder; MOA, mechanism of action; MR, Mendelian randomisation; pQTL, protein quantitative trait loci.

Discussion

We identified novel drug targets and immediate repurposing opportunities for MDD by triangulating genetic evidence and clinical data. Our comprehensive integrated framework strengthens causal inference in target identification to guide repurposing. The target-compound pairs we prioritise span MDD drug development stages. These include long-standing antidepressants, recently approved treatments like esketamine, repurposing compounds in MDD clinical trials or with early clinical evidence not yet formally tested for MDD treatment, and candidates with strong preclinical evidence.

Genetic validation through established targets and mechanisms

Our findings suggest that genetic evidence may inform clinical success in MDD drug development. Specifically, we observed a higher rate of significant targets for phase IV positive control drugs (82%) versus compounds in earlier clinical trial phases I-III (51%). Our results corroborate broader findings that genetically supported compounds for complex traits are more likely to be approved [7]. Additionally, targets of positive control compounds showed the strongest enrichment in brain tissues, validating our focus on brain targets for repurposing.

For monoaminergic targets of approved MDD treatments, risk-increasing expression of *SLC6A4* (encoding the serotonin transporter), *SLC6A3* (dopamine transporter), and *DRD2* (dopamine D2 receptor) aligned with the established therapeutic inhibitory mechanisms of antidepressants, bupropion, and antipsychotics, respectively. Genetic evidence for DRD2 antagonism was consistent across brain regions, including the basal ganglia, aligning with its role in reward processing [46]. By specifically implicating DRD2 antagonism, we provide directional insight into the PGC MDD-3 GWAS findings that identified the *DRD2* gene as the strongest gene-based association and antipsychotic compound enrichment [16]. Beyond monoaminergic signalling in MDD, we also found genetic support for anxiety medications, reflecting the high comorbidity and genetic overlap between these disorders [42–44]. For example, multiple calcium channel subunits showed significant effects in the cortex, aligning with pregabalin's efficacy in depression-anxiety comorbidity [47], and the PGC MDD-3 finding that pregabalin was among the top-enriched compounds [16].

Multi-target genetic evidence for positive control compounds showed both exclusively beneficial and mixed effects profiles. Genetic effects aligned with therapeutic benefits of the dual-action tricyclic antidepressant Amoxapine on serotonergic (via SLC6A4 inhibition) and dopaminergic (via DRD2 antagonism) signalling. Whereas, for compounds with mixed target

effects, our findings likely reflect that not all targets contribute equally to efficacy. NMDA receptor subunit effects supported esketamine's therapeutic mechanisms, with the inhibition of GRIN1 and GRIN2D targets estimated as beneficial, while GRIN2A inhibition showed adverse effects. Our findings are in agreement with the mixed therapeutic and side effect profiles of targeting different NMDA receptor subunits [48,49]. Similarly, among GABA receptor subunits targeted by anxiolytic benzodiazepines, beneficial effects in the cerebellum were estimated for targeting GABRA6, GABRB2, and GABRG2, but adverse effects for GABRP. Our finding corroborates and extends previous MDD drug target research by Li et al. (2025), who identified the benzodiazepine target GABRA1 in a beneficial direction in the cortex [18]. Target-specific genetic effects suggest which receptor subtypes may drive therapeutic benefits versus contribute to side effects [48–50]. Our findings could potentially inform the development of more selective compounds with improved efficacy-to-side-effect profiles for MDD.

Novel therapeutic strategies guided by genetic evidence

Cardiovascular and metabolic repurposing compounds

We found genetic evidence to support the repurposing potential of three types of cardiovascular system drugs for MDD, from different stages in the repurposing pipeline. Among compounds in clinical trials for depression, we found evidence for multiple targets of pentoxifylline, a PDE inhibitor approved for vascular disease [51–54]. We identified four beneficial PDE6 and PDE3 subunits and one with adverse effects, providing a guide for subtype-specific targeting to improve therapeutic efficacy [55]. A meta-analysis of Phase II trials demonstrated that adjunctive pentoxifylline significantly improved depressive symptoms [56]. Moving to compounds with preliminary clinical MDD evidence, which have yet to be formally evaluated in MDD clinical trials, *ACE* gene expression showed a risk-increasing effect in cortical tissue. ACE inhibitors used in the treatment of hypertension and heart failure have demonstrated mental health benefits, with BBB-penetrant compounds like captopril showing antidepressant-like effects [57–59] potentially by reducing oxidative stress and neuroinflammation while enhancing serotonergic signalling [60]. Both PDE inhibitors and ACE inhibitors are widely used and well-tolerated in cardiovascular medicine, adding to their feasibility for repurposing.

Our genetic findings support metformin, a first-line medication for type 2 diabetes, as a repurposing candidate for MDD. We identified risk-increasing effects on MDD for Complex I subunit cortical expression (*NDUFA2*, *NDUFB6*, *NDUFS1* genes), aligning with metformin's inhibitory mechanism on these targets. Our finding complements the identification of another

metformin gene encoding target, *NDUFAF3*, as a novel MDD-associated gene [61]. Animal models demonstrate that metformin exhibits antidepressant and anxiolytic-like effects [62,63], potentially through AMPK activation, which reduces neuroinflammation and modulates serotonergic and glutamatergic signalling [64]. Case-control observational studies suggest metformin is associated with decreased risk of depression, although findings from cohort studies have been mixed [65]. Whilst one phase III trial demonstrated efficacy of metformin in treatment-resistant bipolar depression [66], the only published RCT testing metformin as an adjunctive antidepressant in MDD was retracted [67]. Given our genetic evidence alongside preclinical and observational support, prioritising metformin for clinical trials with MDD as a primary outcome is warranted.

Preclinical evidence supports our findings to explore the repurposing potential of antihypertensive imidazoline I_1 agonists moxonidine and rilmenidine. We found opposite effect directions of *NISCH* (which encodes Nischarin, the proposed imidazoline I_1 receptor) across brain regions and the spinal cord, likely reflecting Nischarin's potential neurotoxic or neuroprotective context-dependent roles in neuroinflammation and neural plasticity [68,69]. The I_1 receptor modulates sympathetic activity through brain stem projections to the spinal cord, regulating CNS and peripheral blood pressure and stress response [68]. I_1 agonist agmatine may act as an endogenous antidepressant [70], with compensatory increased levels in the brain during anxiety in rodent models of stress-response [71,72] alongside *NISCH* downregulation in the amygdala [73]. Nischarin was elevated in the postmortem prefrontal cortex of MDD patients not taking antidepressants and decreased in those taking antidepressants [74], aligning with our risk-increasing effect in brain tissue. Furthermore, Imidazoline I1 agonists exhibit antidepressant-like effects in preclinical models [68]. The antidepressant efficacy of SSRIs and statins may be partially mediated by I_1 receptor activation by agmatine and blocked by I_1 antagonists [75,76]. These findings establish Nischarin as a relevant MDD target through its potential dysregulation in stress-depression pathways and involvement in antidepressant mechanisms.

Cancer repurposing compounds potentially implicated in neuroplasticity

Among our prioritised novel targets for MDD treatment were three proteins currently targeted by BBB-penetrant cancer drugs, with plausible roles in neural function. CDK4 showed opposite directional effects between protein and *CDK4* transcript levels across five brain regions, reflecting its diverse neural functions in regulating neurogenesis [77], neuronal activity [78] and synaptic plasticity [79]. Our hippocampal eQTL finding aligns with evidence that CDK4 inhibition may impair neurogenesis and psychiatric symptom risk, as evidenced by the observed neuropsychiatric side effects of CDK4 inhibitors [80]. The selective CDK4

inhibitor abemaciclib demonstrates fewer neuropsychiatric side effects than less selective alternatives [80,81]. Thus, highly selective modulation of CDK4 signalling could potentially be harnessed for therapeutic effects in MDD while minimising adverse effects.

Similar to CDK4, NTRK3 and MET proteins have potential broad roles in neuroplasticity [82,83]. The *NTRK3* gene encodes the receptor for neurotrophin-3, which modulates cortical monoaminergic transmission, BDNF expression and HPA axis function [82]. We found that increased *NTRK3* transcript levels were associated with elevated MDD risk with colocalisation evidence, corroborating the PGC MDD-3 identification of *NTRK3* as a high-confidence MDD gene through other convergent genomic methods [16]. We advance this robust evidence by directly identifying inhibitors to counteract the genetic risk-increasing effect of NTRK3. The *MET* gene encodes the MET hepatocyte growth factor receptor, which showed consistent risk-increasing effects across the basal ganglia and spinal cord. MET signalling regulates neuroplasticity, neurotrophic pathways, and inflammation [83]. Approved inhibitors for NTRK3 and MET exhibit psychiatric side effects, supporting their neuropsychiatric relevance [84,85]. Our findings direct further investigation of CDK4, NTRK3 and MET inhibitors in MDD. Next steps could include dose-ranging studies to determine if lower doses provide therapeutic effects while minimising psychiatric side effects, and the development of more selective compounds with improved CNS profiles.

Early-stage drug development compounds potentially implicated in neuroinflammation

We identified two enzyme targets modulated by compounds with preclinical depression evidence, yet to be clinically approved for any indication or tested in MDD clinical trials. As such, these targets represent opportunities beyond the repurposing of approved medications. *GLS* expression (encoding glutaminase) showed risk-increasing effects in the cerebellum and cortex, offering a mechanistically distinct approach to glutamatergic modulation compared to approved depression compounds. While NMDA antagonists (e.g. esketamine) block glutamate receptor signalling, glutaminase inhibition reduces glutamate production in activated microglia, directly limiting excitotoxicity and neuroinflammation [86,87]. Similarly, *NOS2* expression (encoding inducible Nitric oxide synthase; iNOS) exhibited consistent risk-increasing effects across three brain regions. Unlike other NOS isoforms, iNOS is primarily induced in glial cells during inflammation, making it a temporal and cell-type-specific target that selectively reduces neuroinflammation without affecting normal NO signalling [88,89]. Both targets and their corresponding inhibitors have promising evidence from animal models. The novel CNS-penetrant glutaminase inhibitor JHU-083 demonstrates antidepressant-like effects in animal models while minimising peripheral side

effects as a pro-drug [86,87]. Preclinical studies in rodents have demonstrated that selective iNOS inhibition exhibits antidepressant-like effects [90,91] and attenuates stress-induced anxiogenic effects [90]. To our knowledge, we provide the first human genomic evidence supporting these early-stage drug development compounds, highlighting the potential for novel MDD therapeutics targeting neuroinflammatory pathways.

Limitations and future directions

Our study has several potential limitations. While prioritising targets with established clinical druggability for rapid translation, our study also incorporated high-quality experimental targets, a broader scope than prior drug target MR studies [17,18]. However, our expanded scope still excluded targets from pQTL/eQTL analyses that may become therapeutically viable as drug development advances [9]. Our *cis*-MR approach examines the effects of individual drug target proteins; yet, in biological systems, these proteins function within complex, interconnected networks and pathways [91]. This makes it challenging to estimate therapeutic effects solely based on modulating single targets in isolation. Drugs often have polypharmacological effects (binding to multiple targets) that can trigger broader network responses and compensatory mechanisms [91,92]. Furthermore, discrepancies between genetic and pharmacological findings (e.g. the direction of effect not aligning with the compound mechanism of known therapeutic effects, such as adverse direction for 8% of approved positive controls) may reflect differences between lifelong genetic effects and acute pharmacological interventions [93], tissue-specific [10] or cell-specific effects [29]. While focusing on *cis*-MR strengthens the biological rationale and reduces the risk of horizontal pleiotropy compared to other approaches, and robust MR estimators were employed as sensitivity analyses, horizontal pleiotropy cannot be entirely ruled out [10]. Only 11% of targets had sufficient power for informative colocalisation results. This is consistent with a general limitation of colocalisation methods, which require strong GWAS associations in both traits for a given *cis*-region [94]. Our analysis of European-associated ancestry data may limit generalisability to other populations [95]. Further experimental validation and clinical studies are needed to confirm the therapeutic potential of novel targets across globally representative populations and diverse biological contexts.

The clinical and biological heterogeneity of MDD challenges the translation of genetically supported targets and compounds into novel, effective treatments. For example, despite genomic support from our study and previous work [18], CRHR1 antagonists regulating the HPA axis have failed in depression clinical trials [96]. Similarly, clinical trials of anti-inflammatory targeting drugs have largely been unsuccessful [97]. A lack of success may

stem from patient heterogeneity obscuring therapeutic effects, with MDD clinical trials often taking a 'one-size fits all' approach [97,98]. Future research could explore genetically supported targets through patient stratification approaches, matching treatments to specific MDD subtypes such as those with stress-induced HPA axis dysregulation or inflammation-driven symptoms [97,98].

Conclusions

Our genetically informed approach corroborated established MDD targets while identifying novel therapeutic candidates for further investigation. We found evidence supporting targets and compounds across development stages, from pre-clinical models to approved drugs, acting in beneficial therapeutic directions. These targets point to multiple pathophysiological pathways in MDD beyond traditional monoaminergic mechanisms. The range of mechanisms reflects the complex neurobiology of MDD, suggesting potential approaches for targeting specific subtypes. Several identified targets have approved drugs with established safety profiles and BBB penetration, offering opportunities for immediate clinical evaluation.

Acknowledgements

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (I-IRISK grant agreement No. 863981). AFS is supported by BHF grants PG/18/5033837, PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223. AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. SB is supported by the Great Ormond Street Hospital Children's Charity. This work was funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee EP/Z000211/1, by the UKRI/NIHR Multimorbidity fund Mechanism and Therapeutics Research Collaborative MR/V033867/1, and by the Rosetrees Trust. The authors acknowledge the use of the UCL Myriad High Performance Computing Facility (Myriad@UCL), and associated support services, in the completion of this work. This research has been conducted using the UK Biobank Resource under application number 12113. We are grateful to the UK Biobank participants. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government, and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. We thank the research participants and employees of 23andMe, Inc. for their contribution to the GWAS summary data used in this study.

Ethical approval

The UK Biobank has ethical approval from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank approval (REC reference: 21/NW/0157).

Data availability

GWAS summary statistics for MDD are available from the Psychiatric Genomics Consortium at https://pgc.unc.edu/for-researchers/download-results/. GWAS summary statistics including 23andMe data require an approved application through 23andMe available to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants (visit https://research.23andme.com/dataset-access/). UK Biobank data are available through application at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access/. Open Targets tractability data can be downloaded from http://ftp.ebi.ac.uk/pub/databases/opentargets/platform/latest/input/target/tractability/. QTL datasets are available from: Blood plasma pQTL data: deCODE (https://www.decode.com/summarydata/), UKB-PPP

(https://www.synapse.org/#!Synapse:syn51364943/), INTERVAL (http://www.phpc.cam.ac.uk/ceu/proteins/), and Gudjonsson (https://www.ebi.ac.uk/gwas/publications/35078996). Brain pQTL data: ROSMAP and Banner (https://www.synapse.org/#!Synapse:syn24172458). CSF pQTL data: Yang (https://dss.niagads.org/datasets/ng00102/). Blood eQTL data: eQTLGen (https://www.eqtlgen.org/). Brain eQTL data: MetaBrain (https://www.metabrain.nl/).

Conflicts of interest

The authors have nothing to disclose.

References

1. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.

3. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:512–6.

4. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4:409–18.

5. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489.

6. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.

7. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624–9.

8. Rusina PV, Falaguera MJ, Romero JMR, McDonagh EM, Dunham I, Ochoa D. Genetic support for FDA-approved drugs over the past decade. Nat Rev Drug Discov. 2023;22:864.

9. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med [Internet]. 2017;9. Available from: http://dx.doi.org/10.1126/scitranslmed.aag1166

10. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255.

11. Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep. 2019;9:18911.

12. Daghlas I, Gill D. Mendelian randomization as a tool to inform drug development using human genetics. Cambridge Prisms: Precision Medicine. 2023;1:e16.

13. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46:2078–89.

14. Gordillo-Marañón M, Zwierzyna M, Charoen P, Drenos F, Chopade S, Shah T, et al. Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nat Commun. 2021;12:6120.

15. Storm CS, Kia DA, Almramhi MM, Bandres-Ciga S, Finan C, International Parkinson's Disease Genomics Consortium (IPDGC), et al. Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nat Commun. 2021;12:7342.

16. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell [Internet]. 2025; Available from: http://dx.doi.org/10.1016/j.cell.2024.12.002

17. Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo X-J. Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacology. 2023;48:270–80.

18. Li Y, Dang X, Chen R, Teng Z, Wang J, Li S, et al. Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression. Nat Hum Behav. 2025;9:806–23.

19. Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, et al. Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity. Sci Adv. 2023;9:eadd4984.

20. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712–21.

21. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–38.

22. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300–10.

23. Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV, et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. 2021;24:1302–12.

24. Robins C, Liu Y, Fan W, Duong DM, Meigs J, Harerimana NV, et al. Genetic control of the human brain proteome. Am J Hum Genet. 2021;108:400–10.

25. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat Genet. 2023;55:377–88.

26. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622:348–58.

27. Brown KK, Hann MM, Lakdawala AS, Santos R, Thomas PJ, Todd K. Approaches to target tractability assessment - a practical perspective. Medchemcomm. 2018;9:606–13.

28. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47:D930–40.

29. Hukerikar N, Hingorani AD, Asselbergs FW, Finan C, Schmidt AF. Prioritising genetic findings for drug target identification and validation. Atherosclerosis. 2024;390:117462.

30. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–9.

31. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization

with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables. Genet Epidemiol. 2017;41:714–25.

32. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783–802.

33. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4:186.

34. Patel A, Ye T, Xue H, Lin Z, Xu S, Woolf B, et al. MendelianRandomization v0.9.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome Open Res. 2023;8:449.

35. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. Genet Epidemiol. 2020;44:313–29.

36. Burgess S, Thompson SG. Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation. CRC Press; 2015.

37. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11:376.

38. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40:304–14.

39. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16:e1008720.

40. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am J Hum Genet. 2022;109:767–82.

41. Duffy Á, Verbanck M, Dobbyn A, Won H-H, Rein JL, Forrest IS, et al. Tissue-specific genetic features inform prediction of drug side effects in clinical trials. Sci Adv. 2020;6:eabb6242.

42. Strom NI, Verhulst B, Bacanu S-A, Cheesman R, Purves KL, Gedik H, et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling [Internet]. medRxiv. 2024. Available from: http://medrxiv.org/lookup/doi/10.1101/2024.07.03.24309466

43. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24:210–26.

44. Coplan JD, Aaronson CJ, Panthangi V, Kim Y. Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches. World J Psychiatry. 2015;5:366–78.

45. Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9:30.

46. Zhao F, Cheng Z, Piao J, Cui R, Li B. Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression? Front Pharmacol. 2022;13:947785.

47. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883–92.

48. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383–400.

49. Egunlusi AO, Joubert J. NMDA receptor antagonists: Emerging insights into molecular mechanisms and clinical applications in neurological disorders. Pharmaceuticals (Basel). 2024;17:639.

50. Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: A mechanistic perspective. Biomolecules. 2022;12:1784.

51. Merza Mohammad TA, Merza Mohammad TA, Salman DM, Jaafar HM. Pentoxifylline as a novel add-on therapy for major depressive disorder in adult patients: A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2024;57:205–14.

52. Yasrebi S-O, Momtazmanesh S, Moghaddam HS, Shahmansouri N, Mehrpooya M, Arbabi M, et al. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial. J Psychosom Res. 2021;150:110635.

53. Farajollahi-Moghadam M, Sanjari-Moghaddam H, Ghazizadeh Hasemi M, Sanatian Z, Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial: a randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol. 2021;36:140–6.

54. El-Haggar SM, Eissa MA, Mostafa TM, El-Attar KS, Abdallah MS. The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Psychother Psychosom. 2018;87:331–9.

55. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290–314.

56. Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology. 2025;33:105–19.

57. Karwowska-Polecka W, Halicka D, Jakubów P, Braszko JJ. The ef-fect of enalapril and captopril on emotional processes in hyperten-sive patients. Psychiatr Pol. 2002;36:591–601.

58. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002;438:1–14.

59. Brownstein DJ, Salagre E, Köhler C. Blockade of the angio-tensin system improves mental health domain of quality of life: ameta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018;52:24–38.

60. Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Hamad RS, Alexiou A, et al. Role of brain renin-angiotensin system in depression: A new perspective. CNS Neurosci Ther. 2024;30:e14525.

61. Meng X, Navoly G, Giannakopoulou O, Levey DF, Koller D, Pathak GA, et al. Multi-ancestry genome-wide association study of major depression aids locus discovery, fine

mapping, gene prioritization and causal inference. Nat Genet. 2024;56:222–33.

62. Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqués MA, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935–48.

63. Mendonça IP, Paiva IHR de, Duarte-Silva EP, Melo MG de, Silva RS da, Oliveira WH de, et al. Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. Int Immunopharmacol. 2022;102:108415.

64. Cheng Y-Y, Yao Q, Miao Y, Guan W. Metformin as a potential antidepressant: Mechanisms and therapeutic insights in depression. Biochem Pharmacol. 2025;233:116773.

65. Zhang Y, Chan VK-Y, Chan SSM, Chan EWY, Lee CH, Wong IC, et al. Effect of metformin on the risk of depression: A systematic review and meta-regression of observational studies. Asian J Psychiatr. 2024;92:103894.

66. Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD study): A randomized, quadruple-masked, placebo-controlled clinical trial: A randomized, quadruple-masked, placebo-controlled clinical trial. J Clin Psychiatry [Internet]. 2022;83. Available from: http://dx.doi.org/10.4088/JCP.21m14022

67. Abdallah MS, Mosalam EM, Zidan A-AA, Elattar KS, Zaki SA, Ramadan AN, et al. The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics. 2020;17:1897–906.

68. Zheng P, Pan C, Zhou C, Liu B, Wang L, Duan S, et al. Contribution of Nischarin/IRAS in CNS development, injury and diseases. J Adv Res. 2023;54:43–57.

69. Smith KL, Jessop DS, Finn DP. Modulation of stress by imidazoline binding sites: implications for psychiatric disorders. Stress. 2009;12:97–114.

70. Yan S, Xu C, Yang M, Zhang H, Cheng Y, Xue Z, et al. The expression of agmatinase manipulates the affective state of rats subjected to chronic restraint stress. Neuropharmacology. 2023;229:109476.

71. Zhu MY, Wang WP, Huang J, Feng YZ, Regunathan S. Bissette Repeated immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels Neurochem. Neurochem Int. 2008;53:346–54.

72. Zhu MY, Wang WP, Cai ZW, Regunathan S. Ordway Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain Eur. Eur J Neurosci. 2008;27:1320–32.

73. Kõks S, Luuk H, Nelovkov A, Areda T, Vasar E. A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain Behav. 2004;3:80–9.

74. Keller B, García-Sevilla JA. Dysregulation of IRAS/nischarin and other potential I1-imidazoline receptors in major depression postmortem brain: Downregulation of basal contents by antidepressant drug treatments. J Affect Disord. 2017;208:646–52.

75. Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology. 2009;57:415–24.

76. Rahangdale S, Fating R, Gajbhiye M, Kapse M, Inamdar N, Kotagale N, et al. Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in mice. Eur J Pharmacol. 2021;892:173739.

77. Artegiani B, Lindemann D, Calegari F. Overexpression of cdk4 and cyclinD1 triggers greater expansion of neural stem cells in the adult mouse brain. J Exp Med. 2011;208:937–48.

78. Pedraza N, Monserrat MV, Ferrezuelo F, Torres-Rosell J, Colomina N, Miguez-Cabello F, et al. Cyclin D1-Cdk4 regulates neuronal activity through phosphorylation of GABAA receptors. Cell Mol Life Sci. 2023;80:280.

79. Li C, Li X, Chen W, Yu S, Chen J, Wang H, et al. The different roles of cyclinD1-CDK4 in STP and mGluR-LTD during the postnatal development in mice hippocampus area CA1. BMC Dev Biol. 2007;7:57.

80. Xiao Z, Cao J, Wu S, Zhou T, Li C, Duan J, et al. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system. CNS Neurosci Ther. 2024;30:e14862.

81. Beukelaers P, Vandenbosch R, Caron N, Nguyen L, Belachew S, Moonen G, et al. Cdk6-dependent regulation of G(1) length controls adult neurogenesis. Stem Cells. 2011;29:713–24.

82. Shatri H, Pranandi M, Ardani Y, Firmansyah I, Faisal E, Putranto R. The role of Neurotrophin 3 (NT-3) on neural plasticity in depression: a literature review. Intisari Sains Medis. 2023;14:1103–8.

83. Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, et al. HGF and MET: From brain development to neurological disorders. Front Cell Dev Biol. 2021;9:683609.

84. Sisi M, Fusaroli M, De Giglio A, Facchinetti F, Ardizzoni A, Raschi E, et al. Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: Analysis of spontaneous reports submitted to the FDA adverse event reporting system. Target Oncol. 2022;17:43–51.

85. Barbieri MA, Russo G, Sorbara EE, Cicala G, Franchina T, Santarpia M, et al. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System. Front Oncol. 2023;13:1268672.

86. Zhu X, Nedelcovych MT, Thomas AG, Hasegawa Y, Moreno-Megui A, Coomer W, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019;44:683–94.

87. Bell BJ, Hollinger KR, Deme P, Sakamoto S, Hasegawa Y, Volsky D, et al. Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice. Brain Behav Immun Health. 2022;23:100478.

88. Liy PM, Puzi NNA, Jose S, Vidyadaran S. Nitric oxide modulation in neuroinflammation

and the role of mesenchymal stem cells. Exp Biol Med (Maywood). 2021;246:2399–406.

89. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829–37, 837a – 837d.

90. Coelho AA, Vila-Verde C, Sartim AG, Uliana DL, Braga LA, Guimarães FS, et al. Inducible nitric oxide synthase inhibition in the medial prefrontal cortex attenuates the anxiogenic-like effect of acute restraint stress via CB1 receptors. Front Psychiatry. 2022;13:923177.

91. Yuan Y, Yu L, Bi C, Huang L, Su B, Nie J, et al. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chin Med. 2025;20:40.

92. Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8:111–28.

93. Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.

94. Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic association data to guide drug discovery and development: Review of methods and applications. Am J Hum Genet. 2023;110:195–214.

95. Zhao H, Rasheed H, Nøst TH, Cho Y, Liu Y, Bhatta L, et al. Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases. Cell Genom. 2022;2:None.

96. Spierling SR, Zorrilla EP. Don't stress about CRF: assessing the translational failures of CRF1antagonists. Psychopharmacology (Berl). 2017;234:1467–81.

97. Miller AH. Advancing an inflammatory subtype of major depression. Am J Psychiatry. 2025;appiajp20250289.

98. Jiang Y, Peng T, Gaur U, Silva M, Little P, Chen Z, et al. Role of corticotropin releasing factor in the neuroimmune mechanisms of depression: Examination of current pharmaceutical and herbal therapies. Front Cell Neurosci. 2019;13:290.